Viridian Therapeutics, Inc.\ VRDN
Viridian Therapeutics, Inc.\ (Nasdaq: VRDN) is an ophthalmology drug developer. Its lead program, veligrotug (Lumvoa), IV anti-IGF-1R, is in Phase 3 for thyroid eye disease (TED). Its next catalyst on record is VRDN-008: Phase 1 healthy volunteer data (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: VRDN-008 — Phase 1 healthy volunteer data (H2 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| veligrotug (Lumvoa) - IV anti-IGF-1R | thyroid eye disease (active and chronic) | antibody | Approved |
| elegrobart (VRDN-003) - SC anti-IGF-1R | thyroid eye disease | antibody | Phase 3 |
| VRDN-008 (half-life extended bispecific FcRn inhibitor) | autoimmune diseases | protein/peptide | Phase 1 |
| VRDN-006 (Fc-fragment FcRn inhibitor) | autoimmune diseases | protein/peptide | Phase 1 |
| Anti-TSHR half-life extended antibody | Graves' disease and TED | antibody | Pre-clinical |
Recent results and decisions
- Jun 29, 2026approval FDA approved Lumvoa (veligrotug-vvze) under Priority Review for thyroid eye disease regardless of activity or duration; first TED label with data in both active and chronic disease; launching immediately.
the U.S. Food and Drug Administration (FDA) has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED).
Filing - Jun 26, 2026approval FDA approved Lumvoa for thyroid eye disease on June 26, 2026, ahead of the target PDUFA date; U.S. launch under way (recap in Q2 earnings release).
The U.S. Food and Drug Administration (FDA) approved Lumvoa for the treatment of TED on June 26, 2026.
Filing - May 5, 2026met REVEAL-2 met primary endpoint: proptosis responder rate 50% (Q4W) and 54% (Q8W) vs 15% placebo at week 24 (p<0.0001); Q4W diplopia responder rate 61% vs 38% (p=0.0118).
REVEAL-2 met its primary endpoint with a highly statistically significant treatment effect
Filing
7 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 ophthalmology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.